排序方式： 共有27条查询结果，搜索用时 15 毫秒
11.
目的:探讨自制活血通络膏预防化疗患者发生静脉炎的效果.方法:采用自身对照的方法,将每例患者的双臂分为观察组和对照组,对照组进行第一个化疗周期,照常规静脉输液进行;观察组进行第二个化疗周期,在输入化疗药同时沿穿刺静脉走向外敷活血通络膏,每次化疗完毕将中药擦掉,观察两组输化疗药血管的变化,进行统计学比较.结果:化疗时中药外敷静脉的方法预防静脉炎较常规输液法效果显著,(P＜0.001).结论:活血通络膏对化疗静脉有保护作用,预防化疗药物引起的静脉炎有良好的效果. 相似文献
12.
谭玉茸 《郧阳师范高等专科学校学报》2003,23(3):73-74,119
对25例患肺结核的高校学生，在全面监督下不住院化疗进行了临床观察总结，其结果：痰菌阴转率100％，病变吸收率100％，说明此种方法可以收到住院化疗的同样效果，值得在高校推广应用。同时，针对高校肺结核发病率不断上升的情况，采取了一些措施，这样对于预防肺结核，控制传染源，降低发病率是十分有益的。 相似文献
13.
14.
目的观察以紫杉醇为主的联合化疗方案治疗转移性乳腺癌的近期疗效和不良反应。方法既往未用过蒽环类化疗者选用TE方案:表阿霉素70~80mg/m2,静滴,第1天,紫杉醇135~175mg/m2,静滴,第2天。既往用过蒽环类化疗者选用TP方案:紫杉醇135~175mg/m2,静滴,第1天,DDP80mg/m2,静滴,分三天用(第2、3、4天)。21~28天为一周期,至少治疗2周期。中位化疗周期数3个(2~6周期)。结果全组70例,CR7例(10.0%),PR36例(51.4%),SD24例(34.3%),PD3例(4.3%),总有效率61.4%。TE方案有效率61.2%,TP方案有效率62.8%。中位肿瘤进展时间TTP9.8个月,中位生存期17.5个月。主要不良反应为骨髓抑制和消化道反应。结论以紫杉醇为主的联合化疗方案对转移性乳腺癌有较好的疗效,毒副反应能忍受,对蒽环类耐药及对铂类抗药的晚期乳腺癌也有很好的疗效。 相似文献
15.
目的：探讨膀胱癌术后膀胱内化疗灌注的护理。方法：回顾64例膀胱癌术后病人,于术后第2周开始行膀胱内灌注化疗药物,与患者进行详细的沟通和健康指导,讲解膀胱内灌注治疗对于预防肿瘤复发的重要性,然后运用直接经尿管注入或钳夹针头灌注法进行药物灌注。结果：64例患者均完成化疗疗程,其中4例患者出现膀胱刺激征,2例发热、1例尿道狭窄。结论：膀胱内灌注化疗需要护士与患者之间有良好的沟通、科学的灌注方法和熟练的操作技术。 相似文献
16.
Jiale Xia Yumeng Xue Bo Lei Lingling Xu Mingzi Sun Na Li Hongyang Zhao Min Wang Meng Luo Chao Zhang Bolong Huang Yaping Du Chun-Hua Yan 《国家科学评论(英文版)》2021,8(7)
2D nanomaterials generally exhibit enhanced physiochemical and biological functions in biomedical applications due to their high surface-to-volume ratio and surface charge. Conventional cancer chemotherapy based on nanomaterials has been hindered by their low drug loading and poor penetration in tumor tissue. To overcome these difficulties, novel materials systems are urgently needed. Hereby, the lanthanide-based porphyrin metal–organic framework (MOF) nanosheets (NSs) with promising cancer imaging/chemotherapy capacities are fabricated, which display superior performance in the drug loading and tumor tissue penetration. The biodegradable PPF-Gd NSs deliver an ultrahigh drug loading (>1500%) and demonstrate the stable and highly sensitive stimuli-responsive degradation/release for multimodal tumor imaging and cancer chemotherapy. Meanwhile, PPF-Gd NSs also exhibit excellent fluorescence and magnetic resonance imaging capability in vitro and in vivo. Compared to the traditional doxorubicin (DOX) chemotherapy, the in vivo results confirm the evident suppression of the tumor growth by the PPF-Gd/DOX drug delivery system with negligible side effects. This work further supports the potential of lanthanide-based MOF nanomaterials as biodegradable systems to promote the cancer theranostics technology development in the future. 相似文献
17.
18.
胃肠道癌术后化疗T细胞亚群和sIL-2R的比较研究 总被引：2，自引：0，他引：2
目的:比较化疗前后T细胞亚群和sIL-2R水平及术后腹腔化疗和静脉化疗T细胞亚群和sIL-2R水平有无差异。方法:54例胃肠道癌症患者,分两组27例,一组接受腹腔化疗,另一组接受静脉化疗,检测血清中T细胞亚群和sIL-2R水平。结果:化疗后血清CD3、CD4和sIL-2R水平较化疗前明显下降(P<0.01)。CD3、CD4、CD8在两治疗组之间相似(P>0.01),但sIL-2R水平腹腔化疗低(0.05P相似文献
19.
舒莲香 《泰州职业技术学院学报》2011,11(1):19-20,54
目的总结43例恶性胸腔积液置管引流注药化疗的护理观察。方法采用Seldinger技术胸腔置管引流后,注入化疗药物,加强导管护理,注意临床观察。结果本组置管43例次,其中导管阻塞9例次（20.9%）,导管滑脱3例次（6.9%）,轻度穿刺点炎症4例次（9.3%）,未见导管断裂,近期胸腔积液完全清除15例（34.8%）,部分清除28例（65.1%）。结论加强对胸腔置管的护理及注意注药的方法是本组治疗的关键,此方法不良反应并发症少,患者痛苦少,治疗疗效佳,胸腔置管引流注入化疗药物是治疗恶性胸腔积液的最有效方法之一。 相似文献
20.
R. L. Gupta Sundeep Jain V. Talwar H. C. Gupta P. S. Murthy 《Indian journal of clinical biochemistry : IJCB》1998,13(2):92-97
After demonstrating that trifluoperazine (TFP) possesses invitro antitubercular activity against drug (single and multidrug) resistantMycobacterium tuberculosis, we initiated preliminary clinical studies in a few patients of tubercular lymphadenitis. Effect of TFP was assessed by testing
the antitubercular activity of the serum of patients receiving TFP in addition to regular therapy. Patients were divided into
two groups of 30 each. For ethical considerations, patients of both groups were treated initially for one month with antitubercular
therapy (ATT) consisting of isoniazid, rifampicin, ethambutol and pyrazinamide and TFP was tried for 15 days only. Patients
of group1 were given a single dose of TFP (5mg/day) daily from days 31 to 45 in addition to ATT, while those in group 2 received
ATT only. Assessment of the antitubercular activity of the serum (testedin vitro in Youmans and Karlson’s liquid medium) revealed that the serum of patients (collected on 45th day) of group1 (ATT+TFP treated)
possessed much higher antitubercular activity than that of group 2 (ATT only treated) patients. Clinical examination indicated
that overall improvement was seen much earlier in group1 (ATT+TFP) patients than in group 2 (ATT alone) patients. At the end
of the follow up period of 6 months with ATT from 46th day onwards to both groups, there were no side effects due to TFP.
Hematology and liver function tests were normal in both the groups. We suggest that TFP has good potential and therefore deserves
further studies either in combination with other drugs of ATT or as one of the drugs of ATT, for the treatment of tuberculosis
due to MDR strains to find a suitable effective dose without side effects. 相似文献